bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
[' psa', 'bimekizumab']
ritchlin et al. bimekizumab in bdmard naive psa. 52 week results. not surprisingly, week 16 outcomes sustained. no joint difference to ada, skin slightly better #acr22 abstr#l02 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC